…
Adia Med Inc operates as a clinical-stage regenerative medicine company. The company offers products and services focused on stem cell therapies, regenerative medicine treatments, and clinical research in areas such as aesthetics, orthopedics, and autoimmune diseases. In addition, the company offers nutritional supplements and biologic products. It sells its products on a direct-to-consumer basis, as well as through other direct to consumer channels. The company was formerly known as Adia Nutrition, Inc. and changed its name to Adia Med Inc in June 2026. Adia Med Inc is based in Winter Park, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Adia Nutrition Inc (OTCQB: ADIA) is an OTC-listed company described as operating in the nutrition/wellness sector, but public disclosures on products, customers and financials are limited. Its long-term outlook appears to depend on commercializing and scaling products, expanding distribution and meeting regulatory requirements; investors may value exposure to consumer health but face significant information gaps.
Key risks include limited disclosure and thin trading liquidity, small scale and execution risk, financing and dilution risk, and regulatory/product‑compliance uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
| Income before tax | -0.40M | -0.18M | -0.00M | -8.61M | -0.60M |
| Minority interest | - | - | - | 0.00M | 0.00M |
| Net income | -0.40M | -0.18M | -0.00M | -8.61M | -0.60M |
| Selling general administrative | 0.47M | 0.18M | 0.00M | 4.30M | 0.83M |
| Gross profit | 0.19M | 0.00M | - | 0.05M | 0.33M |
| Reconciled depreciation | 0.08M | 0.01M | - | - | - |
| Ebit | - | - | - | -6.04M | -0.58M |
| Depreciation and amortization | - | - | 0.00M | - | - |
| Non operating income net other | - | - | - | 0.00M | 0.00M |
| Operating income | -0.37M | -0.17M | -0.00M | -6.04M | -0.58M |
| Other operating expenses | - | - | 0.00M | 0.00M | 0.00M |
| Interest expense | 0.03M | 0.01M | - | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | - | - | - |
| Interest income | 0.00M | 0.00M | - | - | - |
| Net interest income | -0.03M | -0.01M | - | - | - |
| Extraordinary items | - | - | - | 0.00M | 0.00M |
| Non recurring | - | - | - | 0.00M | 0.00M |
| Other items | - | - | - | 0.00M | 0.00M |
| Income tax expense | - | - | - | 0.00M | 0.00M |
| Total revenue | 0.70M | 0.01M | - | 0.20M | 0.76M |
| Total operating expenses | 1.07M | 0.18M | 0.00M | 6.24M | 1.34M |
| Cost of revenue | 0.51M | 0.00M | - | 0.15M | 0.43M |
| Total other income expense net | 0.00M | - | - | -2.57M | -0.02M |
| Discontinued operations | - | - | - | 0.00M | 0.00M |
| Net income from continuing ops | -0.40M | -0.18M | - | -8.61M | -0.60M |
| Net income applicable to common shares | - | - | - | -8.61M | -0.60M |
| Preferred stock and other adjustments | - | - | - | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
| Total assets | 0.59M | 0.67M | 0.00M | 2.99M | 0.23M |
| Intangible assets | - | 0.01M | - | 0.93M | 0.00M |
| Other current assets | - | - | - | 0.00M | 0.00M |
| Total liab | 0.85M | 0.64M | 0.00M | 1.77M | 0.39M |
| Total stockholder equity | -0.26M | 0.03M | -0.00M | 1.21M | -0.17M |
| Deferred long term liab | - | - | - | 0.00M | 0.05M |
| Other current liab | - | - | - | 0.05M | 0.00M |
| Common stock | - | - | 0.00M | 0.02M | 1.16M |
| Capital stock | 0.10M | 0.11M | - | - | - |
| Retained earnings | -15.97M | -15.58M | -0.02M | -9.94M | -1.33M |
| Other liab | - | - | - | 0.00M | 0.00M |
| Good will | - | - | - | 1.05M | 0.00M |
| Other assets | - | - | - | 0.03M | 0.05M |
| Cash | 0.08M | 0.01M | 0.00M | 0.20M | 0.10M |
| Total current liabilities | 0.15M | 0.08M | 0.00M | 1.39M | 0.39M |
| Net debt | 0.52M | 0.36M | 0.00M | - | - |
| Short term debt | - | - | 0.00M | 0.00M | 0.00M |
| Short long term debt | - | - | - | 0.00M | 0.00M |
| Short long term debt total | - | - | 0.00M | - | - |
| Other stockholder equity | - | - | 0.02M | -0.01M | 0.00M |
| Property plant equipment | - | - | - | 0.60M | 0.03M |
| Total current assets | 0.16M | 0.26M | 0.00M | 0.37M | 0.14M |
| Long term investments | 0.08M | 0.08M | - | 0.00M | 0.00M |
| Net tangible assets | - | - | - | -0.77M | -0.17M |
| Short term investments | - | - | - | 0.00M | 0.00M |
| Net receivables | 0.03M | 0.00M | - | 0.10M | 0.03M |
| Long term debt | 0.60M | 0.37M | - | 0.00M | 0.00M |
| Inventory | 0.03M | 0.07M | - | 0.00M | 0.00M |
| Accounts payable | 0.00M | 0.00M | - | 0.66M | 0.04M |
| Total permanent equity | - | - | - | 0.00M | 0.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.00M | 0.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | 0.00M | 0.00M |
| Accumulated other comprehensive income | - | - | 0.00M | 0.00M | 0.00M |
| Additional paid in capital | - | - | - | 0.00M | 0.00M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Preferred stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | 0.00M | 0.00M |
| Treasury stock | - | - | - | 0.00M | 0.00M |
| Accumulated amortization | - | - | - | 0.00M | 0.00M |
| Non currrent assets other | - | - | - | 0.00M | 0.00M |
| Deferred long term asset charges | - | - | - | 0.00M | 0.00M |
| Non current assets total | 0.43M | 0.41M | - | 0.00M | 0.00M |
| Capital lease obligations | 0.20M | 0.26M | - | 0.00M | 0.00M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2004-12-31 | 2003-12-31 |
| Investments | - | - | - | 0.00M | 0.00M |
| Change to liabilities | - | - | - | 0.63M | 0.01M |
| Total cashflows from investing activities | - | - | - | -0.17M | -0.03M |
| Net borrowings | 0.21M | 0.34M | - | -0.01M | 0.01M |
| Total cash from financing activities | 0.28M | 0.37M | 0.00M | 4.19M | 0.29M |
| Change to operating activities | - | - | - | 0.01M | 0.06M |
| Net income | -0.40M | -0.18M | -0.00M | -8.61M | -0.60M |
| Change in cash | 0.07M | 0.01M | 0.00M | 0.10M | -0.02M |
| Begin period cash flow | 0.01M | 0.00M | - | - | - |
| End period cash flow | 0.08M | 0.01M | 0.00M | - | - |
| Total cash from operating activities | -0.18M | -0.34M | -0.00M | -3.92M | -0.29M |
| Issuance of capital stock | 0.07M | 0.03M | - | - | - |
| Depreciation | 0.08M | 0.01M | - | 0.12M | 0.02M |
| Other cashflows from investing activities | - | - | - | -0.10M | -0.10M |
| Dividends paid | - | - | - | 0.00M | 0.00M |
| Change to inventory | -0.03M | -0.14M | - | 0.00M | 0.00M |
| Change to account receivables | -0.03M | 0.00M | - | -0.07M | 0.04M |
| Sale purchase of stock | - | - | - | 0.00M | 0.00M |
| Other cashflows from financing activities | - | - | 0.00M | 0.05M | 0.05M |
| Change to netincome | - | - | - | 3.89M | 0.19M |
| Capital expenditures | 0.01M | 0.03M | 0.00M | 0.07M | 0.03M |
| Change receivables | - | - | - | 0.00M | 0.00M |
| Cash flows other operating | - | - | - | 0.00M | 0.00M |
| Exchange rate changes | - | - | - | 0.00M | 0.00M |
| Cash and cash equivalents changes | - | - | - | 0.00M | 0.00M |
| Change in working capital | 0.10M | -0.19M | - | - | - |
| Stock based compensation | 0.04M | 0.03M | - | - | - |
| Free cash flow | -0.19M | -0.36M | -0.00M | - | - |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| ADIA Adia Nutrition Inc |
- -% |
0.12 | - | - | 9.99 | - | 10.48 |
| HCA HCA Healthcare, Inc. |
15.19 3.30% |
475.52 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 |
| THC Tenet Healthcare Corporation |
-0.10 0.04% |
263.49 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.22 1.52% |
14.00 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 |
| JDHIY JD Health International Inc |
1.31 30.75% |
5.57 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 |
Adia Med Inc operates as a clinical-stage regenerative medicine company. The company offers products and services focused on stem cell therapies, regenerative medicine treatments, and clinical research in areas such as aesthetics, orthopedics, and autoimmune diseases. In addition, the company offers nutritional supplements and biologic products. It sells its products on a direct-to-consumer basis, as well as through other direct to consumer channels. The company was formerly known as Adia Nutrition, Inc. and changed its name to Adia Med Inc in June 2026. Adia Med Inc is based in Winter Park, Florida.
1561 West Fairbanks Avenue, Winter Park, FL, United States, 32789
321-231-2843
3
| Name | Title | Year Born |
|---|---|---|
| Mr. Bill Hodson | CEO & Director | 1967 |
| Ms. - Jenny | Co-Founder | NA |
| Ms. - April | Co-Founder | NA |
| Mr. Todd Smith | Head of Strategic Marketing Team | NA |
| Mr. Larry Powalisz | CEO, President, Secretary & Director | 1964 |
| Ms. Rebecca Miller | Chief Financial Officer | 1976 |
| Mr. Larry Powalisz | CEO, President, Secretary & Chairman | 1964 |
| Ms. Jenny Angeloff Singhal | Co-Founder | NA |
| Ms. April Nugent | Co-Founder | NA |
| Ms. Dawn Bell | Chief Revenue Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.